Search

A new phage therapy company has launched! Phiogen is a spinoff from Baylor College of Medicine, located at Texas Medical Center's Innovation Hub. Based on TAILOR Labs’ phage therapy work, and building on patented technology for evolving pha

Fixed Phage has shown that their technology, which stably immobilizes phages to excipients, can efficiently treat acne when immobilized onto nylon beads and delivered through a cream, reducing the bacterial load on the skin.

SNIPR Biome announced positive interim results from its Phase 1 trial of SNIPR001, a cocktail of four CRISPR-armed phages that targets E. coli, including antibiotic-resistant strains, in the gut. In 36 healthy volunteers (24 on three dose l

Phage utility against Burkholderia cepacia complex species has been restricted by the prevailing paradigm of only using rare, obligately lytic phages, due to the perception that lysogenic phages are therapeutically unsuitable. Philip Lauman

Aleksandra Petrovic Fabijan and colleagues have written a perspective piece on translating phage therapy into the clinic. They delve into the history, turning points, recent studies and successes, and dig into the remaining biological, regu

Adaptive Phage Therapeutics announces a collaboration and license agreement with the Israeli Phage Therapy Center at Hebrew University and Hadassah Medical Center. The agreement grants APT exclusive rights to make, use and sell licensed pha

The Deng lab at the Technical University of Munich is seeking a PhD student to investigate novel therapeutics for preterm infant infections. The team will focus on gut colonisation by pioneer bacterial species and its interruption in preter

Oluwasegun Daramola of the Ibadan Bacteriophage Research Team was interviewed an episode of the Medlab LabCast called Phage Therapy: The Enemy of My Enemy Is My Friend.

Tune in to Science Friday for an interview with Graham Hatfull about phage therapy: “Are Phages a new page in medicine?”

Jagdev Singh and colleagues published a clinical trial announcement that will involve a single-arm, open-labelled study investigating the safety and tolerability of intrabronchial and nebulized phage treatment in children with cystic fibros

Copenhagen-based SNIPR Biome, a CARB-X portfolio company, has developed SNIPR001, a cocktail of CRISPR-armed phages designed to target E. coli. A recent release by Robin Berghaus of CARB-X highlights the potential of SNIPR001 to prevent blo

PLOS ONE survey (N = 787, Prolific) of UK public awareness and acceptance of phage therapy found moderate acceptance, a mean likelihood of 4.71 on a 1-7 scale. Priming participants to think about novel medicines and antibiotic resistance ra

“Resistant bacteria do a lot of taking…” The Center for Disease Control published Diane Shader Smith’s story of her daughter Mallory’s battle against a superbug, how phage therapy could have saved her life, and why more people need to share

The Phage Therapy Today podcast interviewed Johan Wikstroem, the CEO of tolka.ai, about his story in transitioning from tech to biotech and founding a phage therapy company with the goal of treating his own M. abscessus infection and helpin

Kids Research (part of Sydney Children's Hospitals Network) is hosting a webinar on May 19, 2023 at 2:00 PM AEST on phage therapy entitled "Phage Therapy in Australia: STAMPing out problematic infections". The webinar will be presented by P

From Sabrina Green via Twitter: Check out this documentary on #phage therapy in Belgium and Portugal. It is in Portuguese but interviews mostly in English.

Toronto clinician Dr. Greg German: reports the first research use of a phage cocktail to treat an infection in Canada!

Y. Emre Gencay and colleagues have developed engineered phages with CRISPR-Cas machinery to reduce E. coli in mice. The phages, called SNIPR001, were well tolerated in mouse models and minipigs, and out-competed their ancestral wild-type ph

Nature Biotechnology paper on SNIPR001: from a library of 162 wild-type phages, eight with broad E. coli coverage were selected and engineered with tail fibers and CRISPR–Cas machinery to target E. coli. A combination of the four most compl

The Israeli Phage Therapy Center (IPTC) has received 159 requests for phage therapy, with 38% of them being for multi-drug resistant bacteria. Respiratory and bone infections were the most prevalent indications. 20 phage therapy courses wer